Academic Unit of Surgical Oncology, School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, UK.
Lancet Oncol. 2010 Oct;11(10):983-91. doi: 10.1016/S1470-2045(10)70023-1. Epub 2010 May 25.
Angiosarcomas are rare soft-tissue sarcomas of endothelial cell origin that have a poor prognosis. They can arise anywhere in the body, most commonly presenting as cutaneous disease in elderly white men, involving the head and neck and particularly the scalp. They can be caused by therapeutic radiation or chronic lymphoedema and hence secondary breast angiosarcomas are an important subgroup. Recent work has sought to establish the molecular biology of angiosarcomas and identify specific targets for treatment. Interest is now focused on trials of vascular-targeted drugs, which are showing promise in the control of angiosarcomas. In this review we discuss angiosarcoma and its current management, with a focus on clinical trials investigating the treatment of advanced disease.
血管肉瘤是一种罕见的起源于内皮细胞的软组织肉瘤,预后不良。它们可以发生在身体的任何部位,最常见于老年白人男性的皮肤疾病,涉及头部和颈部,特别是头皮。它们可由治疗性放射或慢性淋巴水肿引起,因此继发性乳腺血管肉瘤是一个重要的亚组。最近的工作旨在确定血管肉瘤的分子生物学,并确定治疗的特定靶点。目前的研究重点是血管靶向药物的试验,这些药物在控制血管肉瘤方面显示出了希望。在这篇综述中,我们讨论了血管肉瘤及其目前的治疗方法,重点是探讨治疗晚期疾病的临床试验。